代谢综合征与胰腺癌患者的临床病理特征和预后的相关性研究

Correlation study of metabolic syndrome with clinicopathological features and prognosis in patients with pancreatic cancer

  • 摘要: 目的:探讨代谢综合征(MS)及其组分与胰腺癌患者临床病理特征的相关性和预后影响,为胰腺癌的综合防治、个性化诊疗提供理论参考。方法:回顾性分析2017年1月至2021年12月广西医科大学第一附属医院收治的184例胰腺癌患者的临床资料。根据MS诊断标准,分为非MS组(144例)和MS组(40例)。比较两组临床病理特征。Cox回归模型分析未经抗癌治疗的49例患者预后的影响因素,Kaplan-Meier法分析MS及其组分与预后的关系。结果:与非MS组比较,MS组患者TNM分期晚,肿瘤远处转移发生率高(P< 0.05)。低水平高密度脂蛋白胆固醇(HDL-C)和高血糖均为胰腺癌TNM分期的独立危险因素(P< 0.05)。49例未经抗癌治疗的患者中位生存时间为2.5个月。生存分析显示,TNM分期晚、高血糖为生存时间的独立危险因素(P< 0.05),其中Ⅳ期患者中位生存时间为2.2个月,高血糖是Ⅳ期患者预后的独立危险因素,超重是保护因素(均P< 0.05)。MS患者与非MS患者生存时间比较,差异无统计学意义(P> 0.05)。有无高血压、高甘油三酯(TG)、低HDL-C的患者之间的中位生存时间比较,差异均无统计学意义(均P> 0.05)。结论:MS与胰腺癌患者的临床分期、肿瘤远处转移发生率相关,但尚不能证明是患者生存的影响因素,高血糖和超重分别是患者预后的独立危险因素和保护因素。

     

    Abstract: Objective: To investigate the correlation of metabolic syndrome (MS) and its components with the clinicopathological features in patients with pancreatic cancer and their prognostic impact, so as to provide a theoretical reference for the comprehensive prevention and treatment of pancreatic cancer.Methods: A retrospective analysis was conducted on the case data of 184 patients with pancreatic cancer who received treatment at the First Affiliated Hospital of Guangxi Medical University from January 2017 to December 2021.Based on the diagnostic criteria for metabolic syndrome, the 144 cases were divided into non-MS group (n=104) and MS group (n=40).Cox regression model was used to analyze prognostic factors in 49 patients without anticancer treatment, while Kaplan-Meier method was employed to examine the relationship between MS and its components with prognosis.Results: Compared with the non-MS group, the MS group exhibited advanced TNM stage and a higher incidence rate of distant metastasis (P< 0.05).Low level of high-density lipoprotein cholesterol (HDL-C) and hyperglycemia were independent risk factors for TNM staging of pancreatic cancer(P< 0.05).The median survival time for the 49 patients without anticancer therapy was determined as 2.5 months.Survival analysis showed that advanced TNM stage and hyperglycemia were independent risk factors for survival time (P< 0.05), and the median survival time of stage Ⅳpatients was 2.2 months.Hyperglycemia was an independent risk factor for the prognosis of stage Ⅳpatients, and overweight was a protective factor(both P< 0.05).There was no statistical significance in survival time between MS patients and non-MS patients(P> 0.05), and there was no statistical significance in median survival time between patients with or without hypertension, high triglyceride (TG) and low HDL-C(all P> 0.05).Conclusion: MS is related to clinical stage and incidence of distant metastasis of pancreatic cancer patients, but it has not been proved to be an influencing factor for the survival of patients.Hyperglycemia and overweight are risk factors and protective factors for the prognosis of patients.

     

/

返回文章
返回